Precision Neuroscience Receives FDA Clearance for High-Resolution Cortical Electrode Array

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Milestone Paves the Way for Commercialization, Unlocks New Research Potential

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) — Precision Neuroscience Corporation (Precision), a leader in brain–computer interface (BCI) technology, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Layer 7 Cortical Interface, its high-resolution cortical electrode array, for use in the recording, monitoring, and stimulation of electrical activity on the surface of the brain. The array is a core component of Precision’s fully implantable, wireless brain–computer interface system, which is currently in development. With this clearance, the Layer 7 Cortical Interface is now authorized for commercial use with implantation durations of up to 30 days.

The clearance represents a major milestone for the brain–computer interface field, as it marks the first full regulatory clearance granted to a company developing a next-generation wireless BCI. It also paves the way for Precision to begin marketing its technology for clinical applications, such as intraoperative brain mapping. “This is a foundational moment for Precision,” said Benjamin Rapoport, MD, PhD, Chief Science Officer and Co-Founder. “By introducing the Layer 7 Cortical Interface into clinical settings, we’ll be able to deliver immediate value for patients and neurosurgical teams, enabling real-time neural recording at a fidelity and scale not previously possible.”

Precision will follow the clearance with an expansion of its clinical research program. The company has tested its device in 37 patients to date through clinical study partnerships with leading research institutions, including Mount Sinai Health System, the Perelman School of Medicine at the University of Pennsylvania, West Virginia University’s Rockefeller Neuroscience Institute, and Beth Israel Deaconess Medical Center. Additional collaborations will be announced later this year. These implants have, until now, been limited to short durations during neurosurgical procedures. This clearance allows Precision’s technology to be deployed for longer durations, up to 30 days—for weeks at a time, instead of hours––opening up new possibilities for scientific discovery.

Rapoport emphasized that extended implant durations will enhance Precision’s ability to gather high-quality neural data, which is essential for improving the performance of its brain–computer interface systems. “Neural decoding algorithms, like all AI-driven products, rely on vast amounts of data,” he said. “This regulatory clearance will exponentially increase our access to diverse, high-quality data, which will help us to build BCI systems that work more effectively.”

Michael Mager, Precision’s CEO and Co-Founder, reflected on Precision’s evolution from a startup to a clinical-grade medical technology company: “In just four years since our founding, we’ve gone from an idea to achieving FDA clearance for our cutting-edge cortical array, which we manufacture in a facility that we own and operate. This is a testament to the extraordinary team we have attracted, and their ability to execute across multiple domains. Our mission is to deliver life-changing brain–computer interface technology to the millions of people who stand to benefit from it. This clearance represents a big step forward toward that goal.”

About Precision Neuroscience
Precision Neuroscience is working to provide breakthrough treatments for the millions of people worldwide suffering from neurological illness. The company is building the only brain–computer interface designed to be minimally invasive, safely removable, and capable of processing large volumes of data. To learn more about how Precision is connecting human intelligence and artificial intelligence, visit www.precisionneuro.io.

Media Contact:
media@precisionneuro.io

Staff

Recent Posts

Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025

Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta…

15 hours ago

SlimJaro Canada, Australia, UK, Reviews, Official Website, Discount Code, Trustpilot Complaints

Slimjaro Slimjaro Lakeland, FL, May 03, 2025 (GLOBE NEWSWIRE) -- SlimJaro Canada: The Revolutionary Fat-Burning…

15 hours ago

Javy Protein Coffee Under Review: Best Protein Coffee with Premium Ingredients by Javy Protein Coffee

Discover why Javy Protein Coffee is the best protein coffee for energy, recovery, and flavor.…

15 hours ago

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

PURCHASE, N.Y., May 02, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader…

15 hours ago

INP and Fight For Life Club Foundation Make History: Two Pediatric Living Donor Liver Transplants in One Week

Dallas, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- In a historic medical achievement, the National…

16 hours ago

RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO

STOCKHOLM, May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories…

19 hours ago